Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1231 | Digoxin Wiki | 0.71 |
| drug924 | Cimetidine Wiki | 0.71 |
| drug785 | COVID-surgRES questionaire Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.05 |
| D007239 | Infection NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This is a Phase 1, open-label, multiple-dose trial conducted at a single center. The treatment period will consist of three 6 g doses (18 g) of ZTI-01 as a 1-hour intravenous (IV) infusion (+10 minute window). A total of 30 enrolled subjects will be randomized to undergo a single standardized bronchoscopy with bronchoalveolar lavage (BAL) at one of five sampling times. A total of 6 subjects will be assigned to each BAL-sampling time. Up to ten additional enrolled subjects will act as alternates to obtain 30 evaluable subjects. An evaluable subject is defined as a subject who receives all doses of ZTI-01, undergoes BAL at the randomized sampling timepoint with BAL return volume adequate for testing, and undergoes at least the one blood sampling timepoint that is concurrent with the assigned BAL sampling timepoint, with blood sampling volume that is adequate for testing. The objectives of the study are to assess safety and pharmacokinetics (PK) for a multiple dose regimen of IV-infused ZTI-01.
Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.
Measure: Area under the concentration vs. time curve (AUC0-8 and AUC0-infinity) for ZTI -01 Time: Day 1 to Day 2Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study
Measure: Clearance (CL) of ZTI-01 Time: Day 1 to Day 2Description: Defined as percent penetration of lung epithelial lining fluid (ELF) and alveolar macrophages (AMs). The ratios of ELF and AM concentrations of fosfomycin to simultaneous plasma concentrations will be calculated for each subject and summarized for each sampling time. The median concentrations of fosfomycin from the BAL sampling times will be used to estimate the AUC0-8 of plasma, ELF, and AM. The ratio of AUC0-8 of ELF-to-plasma and AM-to-plasma will be calculated to determine the percent penetration.
Measure: Intrapulmonary pharmacokinetics of ZTI-01 Time: Day 1 to Day 2Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.
Measure: Maximum measured plasma concentration (Cmax) of ZTI-01 Time: Day 1 to Day 2Description: Clinical laboratory evaluations include serum chemistry (albumin, glucose, blood urea nitrogen (BUN), potassium, magnesium, calcium, sodium, total protein, creatinine, triglycerides, total cholesterol, creatine phosphokinase (CPK), phosphorus, alkaline phosphatase (ALP), AST, ALT, total bilirubin, direct bilirubin, and lactate dehydrogenase (LDH)), hematology (CBC with differential (hemoglobin, hematocrit, platelet count, white blood cell (WBC) count, neutrophils, lymphocytes, monocytes, eosinophils, basophils)), coagulation (PT and aPTT), urinalysis (leukocyte esterase, blood, pH, specific gravity, glucose, protein), and plasma urea concentration.
Measure: Number of participants experiencing abnormal clinical laboratory assessments compared to baseline Time: Day 1 to Day 2Description: Physical exams will include assessment of skin, head and neck, lungs, heart, liver, spleen, extremities, lymph nodes, musculoskeletal system/extremities, abdomen, nervous system, weight, height, and body mass index (BMI).
Measure: Number of participants experiencing abnormal physical examination findings compared to baseline Time: Day 1 to Day 2Description: Vital sign measurements will include heart rate, blood pressure, temperature, respiratory rate, and peripheral oxygen saturation.
Measure: Number of participants experiencing abnormal vital sign measurements compared to baseline Time: Day 1 to Day 2Description: QTc, PR, and QRS intervals are expressed in milliseconds (msec).
Measure: Number of participants with prolonged QTc, PR, or QRS interval in electrocardiogram (ECG) readings Time: Day 1 to Day 2Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.
Measure: Terminal elimination half-life (t1/2) of ZTI-01 Time: Day 1 to Day 2Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.
Measure: Terminal-phase elimination rate constant (lambdaz) of ZTI-01 Time: Day 1 to Day 2Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.
Measure: Time to peak concentration (Tmax) of ZTI-01 Time: Day 1 to Day 2Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.
Measure: Volume of ZTI-01 distribution (Vd) Time: Day 1 to Day 2This study is a drug-drug interaction (DDI), pharmacokinetics (PK), safety and tolerability study in adult healthy participants, including Japanese cohort. This study is designed to assess co-administration of probe substrates with gepotidacin in study cohorts 1 to 3 and establishing PK and safety in Japanese participants in cohort 4. Food effect will also be evaluated in cohort 4.
Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Maximum observed concentration (Cmax) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Time to reach maximum observed plasma concentration (Tmax) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Terminal phase half-life (t1/2) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC [0-t]) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: AUC from time 0 (predose) extrapolated to infinite time (AUC[0-infinity]) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: Cmax of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: Lag time before observation of drug concentrations (Tlag) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: Tmax of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: AUC(0-t) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: AUC(0-infinity) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.
Measure: Cohort 3: Cmax of digoxin Time: Up to 96 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.
Measure: Cohort 3: Tlag of digoxin Time: Up to 96 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.
Measure: Cohort 3: Tmax of digoxin Time: Up to 96 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.
Measure: Cohort 3: AUC(0-t) of digoxin Time: Up to 96 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.
Measure: Cohort 3: AUC(0-infinity) of digoxin Time: Up to 96 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.
Measure: Cohort 3: Cmax of midazolam Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.
Measure: Cohort 3: Tlag of midazolam Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.
Measure: Cohort 3: Tmax of midazolam Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.
Measure: Cohort 3: AUC(0-t) of midazolam Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.
Measure: Cohort 3: AUC(0-infinity) of midazolam Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Cmax of gepotidacin after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Tmax of gepotidacin after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC from time 0 (predose) to 24 hours post dose administration (AUC [0-24]) of gepotidacin after a single 1500 mg dose Time: Up to 24 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC from time 0 (predose) to 48 hours post dose administration (AUC [0-48]) of gepotidacin after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-t) of gepotidacin after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-infinity) of gepotidacin after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Cmax of gepotidacin after the first dose of 3000 mg (morning dose) Time: Up to 60 hours post morning dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Tmax of gepotidacin after the first dose of 3000 mg (morning dose) Time: Up to 60 hours post morning dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC from time 0 (predose) to time tau (AUC[0-tau]) of gepotidacin after the first dose of 3000 mg (morning dose) Time: Up to 60 hours post morning dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Cmax of gepotidacin after the second dose of 3000 mg (evening dose) Time: From start of evening dose up to 48 hours post evening dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Tmax of gepotidacin after the second dose of 3000 mg gepotidacin (evening dose) Time: From start of evening dose up to 48 hours post evening dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-tau) of gepotidacin after the second dose of 3000 mg (evening dose) Time: From start of evening dose up to 48 hours post evening dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Accumulation ratio for Cmax (RoCmax) of gepotidacin after the second dose of 3000 mg (evening dose) Time: From start of morning dose up to 48 hours post evening dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Accumulation ratio for AUC (RoAUC) of gepotidacin after the second dose of 3000 mg (evening dose) Time: From start of morning dose up to 48 hours post evening dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-24) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 24 hours post morning dose (first dose) in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-48) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 48 hours post morning dose (first dose) in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-t) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in Period 3Description: AEs will be collected.
Measure: Cohort 4: Number of participants with non-serious adverse events (non-SAEs) Time: Up to Day 16Description: SAEs will be collected.
Measure: Cohort 4: Number of participants with serious adverse events (SAEs) Time: Up to Day 16Description: Number of participants with abnormal vital signs will be assessed.
Measure: Cohort 4: Number of participants with abnormal vital signs Time: Up to Day 16Description: Single 12-lead ECG will be obtained using an ECG machine. Number of participants with abnormal ECG parameters will be assessed.
Measure: Cohort 4: Number of participants with abnormal electrocardiogram (ECG) findings Time: Up to Day 16Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Cohort 4: Number of participants with abnormal hematology parameters Time: Up to Day 16Description: Blood samples will be collected for the assessment of chemistry parameters.
Measure: Cohort 4: Number of participants with abnormal clinical chemistry parameters Time: Up to Day 16Description: Urine samples will be collected for the assessment of urinalysis parameters.
Measure: Cohort 4: Number of participants with abnormal urinalysis findings Time: Up to Day 16Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Cmax of gepotidacin after a single 1500 mg dose under fed conditions Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Tlag of gepotidacin after a single 1500 mg dose under fed conditions Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Tmax of gepotidacin after a single 1500 mg dose under fed conditions Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-t) of gepotidacin after a single 1500 mg dose under fed conditions Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-infinity) of gepotidacin after a single 1500 mg dose under fed conditions Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: AUC(0-24) of gepotidacin Time: Up to 24 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: AUC(0-48) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Tlag of a gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Apparent volume of distribution (Vz/F) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Apparent oral clearance (CL/F) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Total unchanged drug (Ae total) of gepotidacin in urine Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: AUC(0-24) of gepotidacin in urine Time: Up to 24 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: AUC(0-48) of gepotidacin in urine Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Renal clearance of drug (CLr) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Amount of drug excreted in urine in a time interval (Ae[t1-t2]) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 1: Percentage of the given dose of drug excreted in urine (fe%) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: AEs will be collected.
Measure: Cohort 1: Number of participants with non-SAEs Time: Up to Day 14Description: SAEs will be collected.
Measure: Cohort 1: Number of participants with SAEs Time: Up to Day 14Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Cohort 1: Number of participants with abnormal hematology parameters Time: Up to Day 14Description: Blood samples will be collected for the assessment of chemistry parameters.
Measure: Cohort 1: Number of participants with abnormal clinical chemistry parameters Time: Up to Day 14Description: Urine samples will be collected for the assessment of urinalysis parameters.
Measure: Cohort 1: Number of participants with abnormal urinalysis findings Time: Up to Day 14Description: Number of participants with abnormal vital signs will be assessed.
Measure: Cohort 1: Number of participants with abnormal vital signs Time: Up to Day 14Description: Single 12-lead ECG will be obtained using an ECG machine. Number of participants with abnormal ECG parameters will be assessed.
Measure: Cohort 1: Number of participants with abnormal ECG findings Time: Up to Day 14Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: AUC(0-24) of gepotidacin Time: Up to 24 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: AUC(0-48) of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: T1/2 of a gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: Vz/F of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: CL/F of gepotidacin Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: Ae total of gepotidacin in urine Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: AUC(0-24) of gepotidacin in urine Time: Up to 24 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: AUC(0-48) of gepotidacin in urine Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: CLr of gepotidacin in urine Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: Ae(t1-t2) of gepotidacin in urine Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 2: fe% of gepotidacin in urine Time: Up to 48 hours post dose in each periodDescription: AEs will be collected.
Measure: Cohort 2: Number of participants with non-SAEs Time: Up to Day 20Description: SAEs will be collected.
Measure: Cohort 2: Number of participants with SAEs Time: Up to Day 20Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Cohort 2: Number of participants with abnormal hematology parameters Time: Up to Day 20Description: Blood samples will be collected for the assessment of chemistry parameters.
Measure: Cohort 2: Number of participants with abnormal clinical chemistry parameters Time: Up to Day 20Description: Urine samples will be collected for the assessment of urinalysis parameters.
Measure: Cohort 2: Number of participants with abnormal urinalysis findings Time: Up to Day 20Description: Number of participants with abnormal vital signs will be assessed.
Measure: Cohort 2: Number of participants with abnormal vital signs Time: Up to Day 20Description: Single 12-lead ECG will be obtained using an ECG machine. Number of participants with abnormal ECG parameters will be assessed.
Measure: Cohort 2: Number of participants with abnormal ECG findings Time: Up to Day 20Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: Cmax of gepotidacin after the first dose of 3000 mg (morning dose) Time: Up to 60 hours post morning dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: Tmax of gepotidacin after the first dose of 3000 mg (morning dose) Time: Up to 60 hours post morning dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: Tlag of gepotidacin after the first dose of 3000 mg (morning dose) Time: Up to 60 hours post morning dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: AUC(0-tau) of gepotidacin first dose of 3000 mg (morning dose) Time: Up to 60 hours post morning dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: Cmax of gepotidacin after the second dose of 3000 mg (evening dose) Time: From start of evening dose up to 48 hours post evening dose in each PeriodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: Tmax of gepotidacin after the second dose of 3000 mg (evening dose) Time: From start of evening dose up to 48 hours post evening dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: RoCmax of gepotidacin after the second dose of 3000 mg (evening dose) Time: From start of morning dose up to 48 hours post evening dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: RoAUC of gepotidacin after the second dose of 3000 mg (evening dose) Time: From start of morning dose up to 48 hours post evening dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: AUC(0-tau) of gepotidacin after the second dose of 3000 mg (evening dose) Time: From start of evening dose up to 48 hours post evening dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: AUC(0-24) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 24 hours post morning dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: AUC(0-48) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 48 hours post morning dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: AUC(0-t) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: Vz/Fof gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: CL/F of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: T1/2 of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.
Measure: Cohort 3: Trough concentration (Cmin) of digoxin Time: Up to 96 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.
Measure: Cohort 3: t1/2 of digoxin Time: Up to 96 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.
Measure: Cohort 3: Vz/F of digoxin Time: Up to 96 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.
Measure: Cohort 3: CL/F of digoxin Time: Up to 96 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.
Measure: Cohort 3: Cmin of midazolam Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.
Measure: Cohort 3: t1/2 of midazolam Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.
Measure: Cohort 3: Vz/F of midazolam Time: Up to 48 hours post dose in each periodDescription: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.
Measure: Cohort 3: CL/F of midazolam Time: Up to 48 hours post dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: Ae total of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: Ae(t1-t2) of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: AUC(0-tau) of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: AUC(0-24) of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 24 hours post morning dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: AUC(0-48) of gepotidacin in urine following two 3000 mg doses (urine) Time: From start of morning dose up to 48 hours post morning dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: fe% of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 48 hours post morning dose in each periodDescription: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 3: CLr of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in each periodDescription: AEs will be collected.
Measure: Cohort 3: Number of participants with non-SAEs Time: Up to Day 30Description: SAEs will be collected.
Measure: Cohort 3: Number of participants with SAEs Time: Up to Day 30Description: Blood samples will be collected for the assessment of hematology parameters.
Measure: Cohort 3: Number of participants with abnormal hematology parameters Time: Up to Day 30Description: Blood samples will be collected for the assessment of chemistry parameters.
Measure: Cohort 3: Number of participants with abnormal clinical chemistry parameters Time: Up to Day 30Description: Urine samples will be collected for the assessment of urinalysis parameters.
Measure: Cohort 3: Number of participants with abnormal urinalysis Time: Up to Day 30Description: Number of participants with abnormal vital signs will be assessed.
Measure: Cohort 3: Number of participants with abnormal vital signs Time: Up to Day 30Description: Single 12-lead ECG will be obtained using an ECG machine. Number of participants with abnormal ECG findings will be assessed.
Measure: Cohort 3: Number of participants with abnormal ECG findings Time: Up to Day 30Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: T1/2 of gepotidacin after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Vz/F of gepotidacin after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: CL/F of gepotidacin after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Tlag of gepotidacin after the first dose of 3000 mg (morning dose) Time: Up to 60 hours post morning dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Vz/F of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: CL/F of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in Period 3Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: t1/2 of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in Period 3Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Ae total of gepotidacin in urine after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Ae(t1-t2) of gepotidacin in urine after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-tau) of gepotidacin in urine after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-24) of gepotidacin in urine after a single 1500 mg dose Time: Up to 24 hours post dose in Period 1 and Period 2Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-48) of gepotidacin in urine after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: fe% of gepotidacin in urine after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: CLr of gepotidacin in urine after a single 1500 mg dose Time: Up to 48 hours post dose in Period 1 and Period 2Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Ae total of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in Period 3Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: Ae(t1-t2) of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in Period 3Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-tau) of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in Period 3Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-24) of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 24 hours post morning dose in Period 3Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: AUC(0-48) of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 48 hours post morning dose in Period 3Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: fe% of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in Period 3Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.
Measure: Cohort 4: CLr of gepotidacin in urine following two 3000 mg doses Time: From start of morning dose up to 60 hours post morning dose in Period 3Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports